SMILES,log2VDss,log2VDss_pred,Name,CAS #,human VDss (L/kg),human CL (mL/min/kg),"fraction unbound 
in plasma (fu)",MRT (h),terminal  t1/2 (h),Reference,Comments ,Notes,Year of first disclosure,MW,HBA,HBD,TPSA_NO,RotBondCount,moka_ionState7.4,MoKa.LogP,MoKa.LogD7.4
C(CCNCCN1C(=O)c2c(ccc3ccccc23)C1=O)NCCN1C(=O)c2c(ccc3ccccc23)C1=O,3.584962500721156,2.494570775770051,Elinafide,162706-37-8,12.0,5.7,,35.2,52.6,"Phase I and Pharmacokinetic Study of LU79553, a DNA Intercalating Bisnaphthalimide, in Patients With Solid Malignancies Miguel A. Villalona-Calero, Joseph P. Eder, Deborah L. Toppmeyer, Lee F. Allen, Robert Fram, Raja Velagapudi, Michael Myers, Anthony Amato, Kathleen Kagen-Hallet, Betty Razvillas, Donald W. Kufe, Daniel D. Von Hoff, and Eric K. Rowinsky. Journal of Clinical Oncology, 2001 19, 857-869.",LU79553. N=14 across doses ranging from 2 to 24 mg/m2/day.,,1995,520.58,8,2,98.8,10,cationic,3.7,2.9
C(CN)(=O)OC[C@H]([C@@H](c1ccc(cc1)S(=O)(=O)C)O)NC(=O)C(Cl)Cl,-2.9434164716336326,-1.7642201918079226,Thiamphenicol glycinate,2393-92-2,0.13,9.6,0.27,0.23,0.28,"Yang, Bing; Li, Ning; Lu, Yang; Qiu, Zhixia; Zhao, Di; Song, Pengfei; Chen, Xijing. Pharmacokinetics of thiamphenicol glycinate and its active metabolite by single and multiple intravenous infusions in healthy Chinese volunteers. Xenobiotica, 2014, 44, 819-826. ppb: Hashimoto, T. FUNDAMENTAL STUDIES ON PHARMACOKINETICS OF ANTIBIOTICS. PART 1. BINDING OF ANTIBIOTICS TO PLASMA PROTEINS. Chemotherapy (Tokyo). 1973, 21, 38-44","VDss from MRT and clearance. N=24, across 500, 1000, 1500 mg. 30' infusion. Body weight average 58 kg.",,1963,413.27,8,3,135.8,9,cationic,-1.4,-1.8
C(N1CCN(c2nc(nc(n2)NCC=C)NCC=C)CC1)(c1ccc(F)cc1)c1ccc(F)cc1,5.144454313926194,3.319665468020623,Almitrine,27469-53-0,35.37,0.97,0.01,607.0,1344.0,"Bernhard R. Winkelmann, Thomas H. Kullmer, Dieter G. Kneissi, Dietmar Trenk, Hartmut Kronenberger. Low-dose Almitrine Bismesylate in the Treatment of Hypoxemia due to Chronic Obstructive Pulmonary Disease. Chest, 1994; 105, 1383-1391.////ppb: Bromet N; Singlas E. Clinical pharmacokinetics of almitrine dimesylate. Presse medicale, 1984, 13, 2071-2077.","N=7, average weight 64 kg. 60 mg dose. VD reported taken as VDss after calculation from clearance and t 1/2 yielded a much higher value. MRT from clearance and VDss.",,1970,477.55,7,2,69.2,10,neutral,6.0,6.0
C(SP(O)(O)=O)CNCCCN,-3.473931188332412,-2.411354399249615,Amifostine,20537-88-6,0.09,30.65,,0.05,0.15," LESLIE M. SHAW, PH.D., ANDREW T. TURRISI, M.D., DONNA J. GLOVER, M.D., HEATHER S. BONNER, B.S., A. LORRAINE NORFLEET, B.S., CLARE WEILER, R.N.
AND MORTON M. KLIGERMAN, M.D. HUMAN PHARMACOKINETICS OF WR-2721. Int. J. Radiation Oncology Bio. Phys.. 1986, 12, 1501-1504.","WR-2721, NSC 296961. 12 patients with different types of tumor. 70.8 kg average weight. 150 mg/m2, 10 seconds injection.",,1969,214.22,5,4,95.6,7,cationic,-1.4,-3.8
C([C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(NCC(N[C@@H](C(N[C@@H](C(C)C)C(O)=O)=O)CC(C)C)=O)=O)CCC(N)=O)=O)CC(C)C)=O)CC(C)C)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)CC(C)C)=O)CCCNC(N)=N)=O)C)=O)CO)=O)CC(O)=O)=O)CCCNC(N)=N)=O)CC(C)C)=O)CCCNC(N)=N)=O)CO)=O)CC(C)C)=O)CCC(O)=O)=O)CO)=O)[C@@H](C)O)=O)NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](Cc1[nH]ccn1)N)=O)CO)=O)CC(O)=O)=O)=O)[C@@H](C)O)=O)c1ccccc1,-5.058893689053568,-3.846518435943137,Secretin (porcine),1393-25-5,0.03,5.95,,0.08,0.13,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-136_SecreFlo_BioPharmr.pdf. Accessed on May 17 2017,"Secreflo. Secretin (porcine), 15-L-glutamic acid-16-glycine-. ChiRoClin. MW= 3056.42. Synthetic but identical to porcine peptide. Cross-over study with human peptide N=12, 0.4 ug/kg iv in human. 77.2 kg average weight. Data digitized from plot reported in biopharmaceutics review. No AUC reported. Clearance reported as 487 mL/min. Converted in units of mL.min-1.kg-1 yields 6.31 mL.min-1.kg-1. 6% difference",,1907,3056.39,85,52,1415.7,109,zwitterionic,-9.0,-9.0
C1(C2=C([C@H](C[C@]1([C@H]([C@H]1[C@](C(=O)[C@@H]2OC)([C@H](C[C@@H]2[C@]1(CO2)OC(=O)C)OC)C)OC(=O)c1ccccc1)O)OC(=O)[C@@H]([C@H](c1ccccc1)NC(=O)OC(C)(C)C)O)C)(C)C,5.584962500721156,4.240447536762812,Cabazitaxel,183133-96-2,48.0,11.0,0.24,72.7,74.5,"Mita, Alain C.; Denis, Louis J.; Rowinsky, Eric K.; DeBono, Johann S.; Goetz, Andrew D.; Ochoa, Leonel; Forouzesh, Bahram; Beeram, Muralidhar; Patnaik, Amita; Molpus, Kathleen; Semiond, Dorothee; Besenval, Michele; Tolcher, Anthony W. Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors. Clin.Cancer Res. 2009, 15,723-730. ppb: Men, Lei; Lin, Hong-li; Shao, Yan-jie; Zhao, Yun-li; Zhao, Xing; Tang, Xing; Yu, Zhi-guo. Determination of human plasma protein binding rate of cabazitaxel by UPLC-​MS​/MS. Zhongguo Xinyao Yu Linchuang Zazhi, 2014, 33, 379-383. Data from abstract and using mid-concentration range. 2-fold lower at high concentration range (fu 0.12) but similar at low concentration. Taken from abstract in English.","XRP6258 or RPR116258A or Jevtana. 23 patients overall. Doses from 10 to 25 mg/m2 as 1 hour infusion. Weighted average and 1.73m2/70kg factor used. Reported (weighted) average of clearance and VDss 26.77 L/h/m2 and 1942.8 L/m2, respectively. MRT=VDss/Cl.",,1996,835.93,15,3,202.4,14,neutral,4.0,4.0
C1(c2ccccc2)(c2ccccc2)C(=O)N(C(=O)N1)COP(=O)(O)O,-4.058893689053568,-2.969399364732705,Fosphenytoin,93390-81-9,0.06,3.5,0.05,0.17,0.16,"Aweeka, Francesca T.; Gottwald, Mildred D.; Gambertoglio, John G.; Wright, Teresa L.; Boyer, Thomas D.; Pollock, Alan S.; Eldon, Michael A.; Kugler, Alan R.; Alldredge, Brian K. Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia (1999), 40(6), 777-782.  ",Dosed and monitored as phosphenytoin. Healthy subjects only. 0.37 g in 30' infusion.,"Aweeka, Francesca T.; Gottwald, Mildred D.; Gambertoglio, John G.; Wright, Teresa L.; Boyer, Thomas D.; Pollock, Alan S.; Eldon, Michael A.; Kugler, Alan R.; Alldredge, Brian K. Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia (1999), 40(6), 777-782.  ",1984,362.27,8,3,116.2,5,anionic,1.7,-3.3
C1C[C@H](CC[C@@]21c1cc(OCC)ccc1N(S(=O)(c1c(cc(C(NC(C)(C)C)=O)cc1)OC)=O)C2=O)OCCN1CCOCC1,2.807354922057604,1.7369561069370545,Satavaptan,185913-78-4,7.0,12.3,0.1,9.4,10.4,"Satavaptan - EMA Approval Package
Withdrawal Report EMEA/CHMP/316130/2008. Accessed through Pharmapendium.","Data taken at lowest 91 mg) dose. Very tight at 5 and 10 mg doses as well. Somewhat higher (both VDss and clearance but well within two-fold) at higher doses (25, 50 and 100 mg). 70 kg assumed and MRT from VDss and clearance. ",Seemingly biliary but not clear from EMA package.,1997,643.79,11,1,123.7,10,neutral,3.5,3.2
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,3.321928094887362,2.292600316744743,Bortezomib,179324-69-7,10.0,19.0,0.17,8.8,18.0,"Papandreou CN, Daliani D, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, and Logothetis CJ (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.  J. Clin. Oncol. 22: 2108-2121.  Velcade Product Label.",,,1996,384.24,8,4,124.4,9,neutral,0.8,0.8
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)NCCCNCCCCN)OS(=O)(=O)O,-2.120294233717712,-1.0702320115456054,Squalamine,148717-90-2,0.23,1.2,,3.2,9.5,"Hao D, Hammond LA, Eckhardt SG, Patnaik A, Takimoto CH, Schwartz GH, Goetz AD, Tolcher AW, McCreery HA, Mamun K, Williams JI, Holroyd KJ, and Rowinsky EK (2003) A phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.  Clin. Canc. Res. 9: 2465-2471.",VDss calculated from C vs t data obtained by digitization of the representative plot provided in the report.,,1993,627.96,8,5,133.9,16,cationic,3.8,0.76
CC1(C)\C(=C\C=C\C=C\C=C/C2=[N+](CCCCS(=O)(=O)[O-])c3ccc4ccccc4c3C2(C)C)\N(CCCCS(=O)(=O)O)c5ccc6ccccc6c15,-4.836501267717121,-3.2504085776468394,Indocyanine Green,3599-32-4,0.035,6.8,0.05,0.086,0.065,"Vanakoski J, Idanpaan-Heikkila JJ, and Seppala T (1996) Exposure to high environmental temperature in the sauna does not change plasma indocyanine green (ICG) clearance in healthy subjects.  Pharmacol. Toxicol. 78: 94-98.   IC-Green Product Label.",,Reported CAS number of Na salt. Structure without Na. CAS number of component: 28782-33-4,1958,752.98,8,1,117.8,14,anionic,5.4,3.1
CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@]5(C2(C)C)[C@H]([C@@H]1OC(=O)[C@@H]([C@H](CC(C)C)NC(=O)OC(C)(C)C)O)OC(=O)O5)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)OC(=O)C,3.7897292513757694,2.5105853481491875,Ortataxel,186348-23-2,13.83,8.12,,28.39,30.1,"N. Ramnath, J. Hamm, G. Schwartz S. Holdenc,S.G. Eckhardt, M.R. Vredenburg,  R.J. Bernacki C. Lathiad, P. Kanter, P.J. CreavenA Phase I and Pharmacokinetic Study
of BAY59: A Novel Taxane. Oncology 2004;67:123–129","BAY 59-8862. SB-T 101131
 N=25 weight averaged across doses from 30 to 100 mg/m2. 70 kg average weight assumed. MRT froim VDss and clearance.",,1997,871.92,18,3,245.8,15,neutral,3.6,3.6
CCC#CC[C@H](C)[C@H](O)C#C[C@H]1[C@H](O)C[C@@H]2C\C(=C/COCC(=O)O)\C[C@H]12,-3.643856189774725,-2.286824468178109,Cicaprost,94079-80-8,0.08,3.8,,0.35,1.1,"Hildebrand M, Staks T, Schutt A, and Matthes H (1989) Pharmacokinetics of 3H-cicaprost in healthy volunteers.  Prostaglandins  37: 259-273.",VDss was calculated from MRT from a paper cited in the reference. ,,1984,374.47,5,3,87.0,10,anionic,2.6,-0.63
CCCCCCCCCCCC(=O)CC(=O)N[C@H]1[C@@H](OP(=O)(O)O)O[C@H](CO[C@@H]2O[C@H](COC)[C@@H](OP(=O)(O)O)[C@H](OCC[C@@H](CCCCCCC)OC)[C@H]2NC(=O)CCCCCCCCC\C=C/CCCCCC)[C@@H](O)[C@@H]1OCCCCCCCCCC,-4.380821783940931,-2.8044044669590256,Eritoran,185955-34-4,0.048,0.013,,62.0,51.0,"Wong YN, Rossignol D, Rose JR, Kao R, Carter A, and Lynn M (2003) Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study.  J. Clin. Pharmacol. 43: 735-742.  Rossignol DP, Wasan KM, Choo E Yau E, Wong N, Rose J, Moran J, and Lynn M (2004) Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers.    Antimic. Agents Chemother. 48: 3233-3240.",Protein binding driven by lipoproteins--not reported directly,,1996,1313.66,21,7,293.6,59,anionic,9.0,1.7
CCCCCNC(=O)c1coc(n1)[C@H]2[C@@H](Cc3ccccc3CCC(=O)O)[C@@H]4CC[C@H]2O4,2.137503523749935,0.9687474494136724,Ifetroban,143443-90-7,4.4,6.4,,11.0,22.0,"Dockens RC, Santone KS, Mitroka JG, Morrison RA, Jemal M, Greene DS, and Barbhaiya RH (2000) Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans.  Drug Metab. Dispos. 28: 973-980.",,,1992,440.53,7,2,102.0,11,anionic,4.0,1.2
CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O,1.263034405833794,0.025971159619551,Alprostadil,745-65-3,2.4,45.4,,0.9,1.9,"W. Cawello , H. Schweel , R. Miiller, R. Bonn, H.W. Seyberth. Metabolism and pharmacokinetics of prostaglandin E1 administered
by intravenous infusion in human subjects. Eur J Clin Pharmacol (1994) 46:275-277","PGE1. Plot available for digitization. Calculation perforrmed via Phoenix after digitization. Dose 60 ug 2h of infusion, N=12",,1956,354.48,5,3,94.8,13,anionic,3.5,0.93
CCCCc1nc(c(c(=O)n1Cc2ccc(cc2)c3ccccc3c4[nH]nnn4)CC(=S)N(C)C)C,-0.7369655941662062,0.414836963909782,Fimasartan,247257-48-3,0.6,9.6,,1.1,5.5,"Jong-Lyul Ghim, Soo Heui Paik,  M. Hasanuzzaman, Yong Ha Chi, Hyang-Ki Choi,  Dong-Hyun Kim,  Jae-Gook Shin.  Absolute Bioavailability and Pharmacokinetics of the Angiotensin II Receptor Antagonist Fimasartan in Healthy Subjects. J. Clin. Pharmacol. 2016, 56, 576-580.","N=16, 30 mg dose, 1 h infusion. No average weight reported but data available on weight basis. ",,1999,501.65,8,1,92.6,10,cationic,4.1,0.71
CCCc1nc2c(C)cc(cc2n1Cc3ccc(cc3)c4ccccc4C(=O)O)c5nc6ccccc6n5C,2.405992359675837,1.3539588640986084,Telmisartan,144701-48-4,5.3,8.4,0.004,11.0,20.0,"Stangier J, Schmid J, Turck D, Switek H, Verhagen A, Peeters PAM, van Marle SP, Tamminga WJ, Sollie FAE, and Jonkman JHG (2000) Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers.  J. Clin. Pharmacol. 40: 1312-1322.",,,1992,514.62,6,1,72.9,7,anionic,7.7,4.7
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,7.129283016944966,6.123746122287708,Chloroquine,54-05-7,140.0,4.1,0.43,740.0,570.0,"White NJ (1985) Clinical pharmacokinetics of antimalaria drugs.  Clin. Pharmacokinet.  10: 187-215.  Aderounmu AF, Salako LA, Lindstroem B, Walker O, and Ekman L (1986) Comparison of the pharmacokinetics of chloroquine after single intravenous and intramuscular administration in healthy Africans.  Br. J. Clin. Pharmacol. 22: 559-564.",,,1974,319.87,3,1,28.2,8,cationic,5.3,2.0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,9.451211111832327,7.032184240783671,Hydroxychloroquine,118-42-3,700.0,11.0,0.57,1300.0,850.0,"Tett SE, Cutler DJ, Day RO, and Brown KF (1988) A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers. Br, J. Clin. Pharmacol. 26: 303-313.  Brocks DR, Skeith KJ, Johnston C, Emamibafrani J, Davis P, Russell AS, and Jamali F (1994) Hematologic disposition of hydroxychloroquine enantiomers. J. Clin. Pharmacol. 34: 1088-1097. ",,,1891,335.87,4,2,48.4,9,cationic,4.1,1.5
CCOC(=O)C1=C(COCCN)NC(=C(C1c2ccccc2Cl)C(=O)OC)C,4.087462841250339,2.9277281703961977,Amlodipine,88150-42-9,17.0,7.0,0.005,40.0,34.0,"Faulkner JK, McGibney D, Chasseaud LF, Perry JL, and Taylor IW (1986) The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br. J. Clin. Pharmacol. 22: 21-25.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1998) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ",VDss calculated from C vs t data obtained by digitization of the plot in Faulkner et al.,,1983,408.88,7,2,99.9,10,cationic,2.0,0.44
CCOc1ccccc1OCCN[C@H](C)Cc2ccc(OC)c(c2)S(=O)(=O)N,-2.251538766995965,-1.207001200075048,Tamsulosin,106133-20-4,0.21,0.62,0.01,5.6,6.8,"van Hoogdalem E, Soeishi Y, Matsushima H, and Higuchi S (1997) Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling.  J. Pharm. Sci.  86: 1156-1161.  Matsushima H, Kamimura H, Soeishi Y, Watanabe T, Higuchi S, and Tsunoo M (1998) Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans.  Drug Metab. Dispos. 26: 240-245.",,,1986,408.51,7,2,99.9,11,cationic,2.5,1.6
CC[C@@]1(c2cc-3n(c(=O)c2COC1=O)Cc4c3nc5ccc(cc5c4)O)O,-2.1844245711374275,-0.9289580002193448,"Hydroxycamptothecin, 10-",19685-09-7,0.22,2.23,,1.63,1.67,"LI Su, ZHANG Li, GUANG Zhong-zhen, ZHAN Jing, LI Yu-yan , JIANG Wen-qi. Absolute bioavailability of hydroxycamptothecin tablets in cancer patients. Chin. J. Clin. Pharmacol. 2005, 22, 46-49.(written in Chinese) ","N=8, 12 mg.m-2 dose, conversion factor 1.73m2/70kg, 30 minutes infusion. Data digitized and PK parameters calculated via PKSolver. AUC reported as 2171 ug.h.L-1 (not specified); AUS (inf) calculated as 2211 ng.h.mL-1. 2% difference.",,1969,364.35,7,2,101.6,1,neutral,1.4,1.4
CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,-1.736965594166206,0.0018587185567453,"Sitosterol, β-",83-46-5,0.3,0.02,,250.0,372.4,"Duchateau, Guus; Cochrane, Brett; Windebank, Sam; Herudzinska, Justyna; Sanghera, Davindera; Burian, Angela; Mueller, Markus; Zeitlinger, Markus; Lappin, Graham. Absolute oral bioavailability and metabolic turnover of β-​sitosterol in healthy subjects. Drug Metab. Disp. 2012, 40, 2026-2030.","Nimbosterol. Betaprost. Angelicin. N=6, male volunteers. 2.9 to 4.2 ug doses. 70 kg assumed as average weight. MRT from clearance and VDss.",,1908,414.71,1,1,20.2,6,neutral,9.0,9.0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,5.044394119358453,2.970422258086576,Azithromycin,83905-01-5,33.0,10.0,0.88,57.0,69.0,"Luke DR, Foulds G, Cohen SF, and Levy B (1996) Safety, toleration, and pharmacokinetics of intravenous azithromycin.  Antimic. Agents Chemother.  40: 2577-2581.  Foulds G, Shepard RM, and Johnson RB (1990) The pharmacokinetics of azithromycin in human serum and tissues.  J. Antimic. Chemother. 25(Suppl. A):  73-82.",Protein binding is concentration dependent; cited value measured at concentrations observed after IV dosing.,,1953,748.98,14,5,180.1,7,cationic,2.2,-0.18
CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)O[C@H]([C@@H](NC(=O)c1ccccc1)c2ccccc2)C(=O)O[C@H]3C[C@@]4(O)[C@@H](OC(=O)c5ccccc5)[C@@H]6[C@@]7(CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(=O)C)C(=C3C)C4(C)C)OC(=O)C,-3.878321443411747,-1.8800185280613704,DHA Paclitaxel,199796-52-6,0.068,0.025,0.0038,45.0,60.0,"Sparreboom A, Wolff AC, Verweij J, Zabelina Y, van Zomeren DM, McIntire GL, Swindell CS, Donehower RC, and Baker SD (2003) Disposition of docosahaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.  Clin. Cancer Res. 9: 151-159.",Pharmacokinetic paremeters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1997,1164.38,16,3,227.4,30,neutral,9.0,9.0
CN(C)CCNc1ccc2c3c(nn2CCNCCO)c4cnccc4C(=O)c13,5.832890014164741,3.944291305897892,Topixantrone,156090-18-5,57.0,27.0,,39.0,45.0,"Mross K, Scheulen ME, Licht T, Unger C, Richly H, Stern AC, Kutz K, Camboni MG, Barbieri P, Verdi E, Vincenzi B, and Bernareggi A (2004) Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthropyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase 1 study group trial of the Central European Society of Anticancer Drug Research (CESAR).  Anti-Cancer Drugs 15: 15-22.",BBR 3576,,1994,394.47,8,3,95.3,9,cationic,0.69,-1.4
CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(NC(=O)CNC(C)(C)C)c(O)c4C(=O)C3=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)N)N(C)C,3.584962500721156,1.9855915442073349,Tigecycline,220620-09-7,12.0,3.8,0.2,53.0,48.0,"Muralidharan G, Micalizzi M, Speth J, Raible D, and Trpy S (2005) Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.  Antimic. Agents Chemother.  49: 220-229.  Doan TL, Fung HB, Mehta D, and Riska PF (2006) Tigecycline: a glycylcycline antimicrobial agent.  Clin. Ther. 28: 1079-1106.",,,1999,585.65,13,7,205.8,6,cationic,-0.11,-2.9
CN1CCN(CC1)C2=Nc3cc(Cl)ccc3Nc4ccccc24,0.6780719051126377,1.7299167039830383,Clozapine,5786-21-0,1.6,2.5,0.055,11.0,10.0,"Cheng YF, Lundberg T, Bondesson U, Lindstrom L, and Gabrielsson J (1988) Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur. J. Clin. Pharmacol. 34: 445-449.   Schaber G, Stevens I, Gaertner HJ, Dietz K, and Breyer-Pfaff U (1998) Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance.  Br. J. Clin. Pharmacol. 46: 453-459. ",,,1963,326.82,4,1,30.9,1,cationic,4.5,4.1
CN1CC[C@]23[C@H]4Oc5c(O)ccc(C[C@@H]1[C@@H]2C=C[C@@H]4O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O)C(=O)O)c35,-3.0588936890535687,-1.7115292346581554,Morphine-6-Glucuronide,20290-10-2,0.12,2.2,0.67,0.91,1.4,"Lotsch J, Weiss M, Kobal G, and Geisslinger G (1998) Pharmacokinetics of morphine-6-glucuronide and its formation from morphine after intravenous administration.  Clin. Pharmacol. Ther. 63: 629-639.//ppb: Mashayekhi, S. O.; Ghandforoush-Sattari, M.; Buss, D. C.; Routledge, P. A.; Hain, R. D. W. Impact of anti-​cancer drugs and other determinants on serum protein binding of morphine 6-​glucuronide. Daru, Journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2010, 18, 107-113.",,,1968,461.46,10,5,149.1,3,zwitterionic,-0.47,-2.4
CNCCCC12CCC(c3ccccc13)c4ccccc24,5.491853096329675,4.3501890615457866,Maprotiline,10262-69-8,45.0,14.0,0.11,54.0,51.0,"Maguire KP, Norman TR, Burrows GD, and Scoggins BA (1980) An evaluation of maprotiline intravenous kinetics and comparison of two oral doses.  Eur. J. Clin. Pharmacol.18: 249-254.  Lynn K, Braithwaite R, Dawling S, and Rosser R (1981) Comparison of the serum protein binding of maprotiline and phenytoin in uraemic patients on haemodialysis.  Eur. J. Clin. Pharmacol. 19: 73-77.","VDss calculated from reported compartmental paramaters included in the reference by Maguire, et al.",,1966,277.4,1,1,12.0,4,cationic,4.1,1.7
CNCC[C@@H](Oc1ccccc1C)c2ccccc2,-0.2344652536370229,0.7738432682961838,Atomoxetine,83015-26-3,0.85,9.3,0.02,1.5,5.2,Strattera Product Label,CYP2D6 EM data MRT is calculated as VD/CL; CL was calculated as CLpo/F (F=63%),,1982,255.35,2,1,21.3,6,cationic,3.6,1.5
CN[C@@H]1C[C@H]2OC(C)([C@@H]1OC)n3c4ccccc4c5c6[C@@H](O)NC(=O)c6c7c8ccccc8n2c7c35,-2.736965594166206,-1.478848720373156,"Hydroxystaurosporine, 7-",112953-11-4,0.15,0.0037,0.0022,680.0,790.0,"Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, and Kobayashi S (1998) Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.  Canc. Res. 58: 3248-3253.  Dees EC, Baker SD, O'Reilly S, Rudek MA, Davidson SB, Aylesworth C, Elza-Brown K, Carducci MA, and Donehower RC (2005) A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.  Clin. Canc. Res.  11: 664-671.",UCN-01. Used data from 95 mg/m2 group.,,1987,482.53,8,3,89.7,2,cationic,2.5,-0.29
COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4,-1.15200309344505,0.0562385428364148,Tubocurarine,57-94-3,0.45,3.4,0.58,2.2,2.0,"Razman IM, Shanks CA, and Triggs EJ (1978) Studies of d-tubocurarine pharmacokinetics in humans and dogs.  Anaesth. Intens. Care 6: 30-35.  Ghoneim MM, Kramer SE, Bannow R, Pandya H, and Routh JI (1973) Binding of d-tubocurarine to plasma proteins in normal man and in patients with hepatic or renal disease.  Anesthesiol.  39: 410-415.",CAS number reported refers to chloride salt. Parent cation CAS number 57-95-4. Pharmacokinetic parameters determined from reported two-compartment model parameters.,,1935,609.73,8,2,80.6,2,cationic,4.7,3.9
COc1cc2c(CCN[C@]23CS[C@H]4[C@H]5[C@@H]6N(C)[C@@H](Cc7cc(C)c(OC)c(O)c67)[C@H](O)N5[C@@H](COC3=O)c8c9OCOc9c(C)c(OC(=O)C)c48)cc1O,4.643856189774724,3.152227656518532,Trabectedin,114899-77-3,25.0,12.0,0.06,35.0,44.0,"Lau L, Supko JG, Blaney S, Harshon L, Seibel N, Krailo M, Qu W, Malkin D, Jimeno J, Bernstein M, and Baruchel S (2005) A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors.  A children's oncology group study.  Clin. Canc. Res.  11: 672-677. ppb: Jan Handrick Beumer, L. Lopez-Lazaro, Jan H.M. Schellens, Jos H. Beijnen, Olaf van Tellingen. Evaluation of Human Plasma Protein Binding of Trabectedin (Yondelis™,ET-743). Current Clinical Pharmacology, 2009, 4, 38-42",Note: Pharmacokinetic data were determined in children.,,1987,761.84,14,4,168.7,4,cationic,1.8,1.2
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,4.523561956057013,3.399698609195812,Gefitinib,184475-35-2,23.0,12.0,0.0889999999999999,32.0,34.0,"Swaisland, HC, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH, and Duvauchelle T (2005) Single-dose clinical pharmacokinetics studies of gefitinib.  Clin. Pharmacokinet. 44: 1165-1177.  McKillop D, Hutchison M, Partridge EA, Bushby N, Cooper CMF, Clarkson-Jones JA, Herron W, and Swaisland HC (2004) Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man.  Xenobiotica 34: 917-934",,,1986,446.9,7,1,68.7,8,cationic,4.3,3.9
COc1ccc(Cl)cc1[C@]2(F)C(=O)Nc3cc(ccc23)C(F)(F)F,3.321928094887362,1.755692827485635,Maxipost,187523-35-9,10.0,15.0,0.0038,11.0,37.0,"Zhang D, Krishna R, Wang L, Zeng J, Mitroka J, Dai R, Narasimhan N, Reeves RA, Srinivas NR, and Klunk LJ (2005) Metabolism, pharmacokinetics, and protein covalent binding of radiolabeled maxipost (BMS-204352) in humans.  Drug Metab. Dispos. 33: 83-93.  Krishna R, Yao M, Kaczor D, Vachharajani N, and Srinivas NR. (2001) In vitro protein binding studies with BMS-204352: lack of protein binding displacement interaction in human serum.  Biopharm. Drug Dispos. 22: 41-44.",Flindokalner. BMS-204352,,1997,359.7,3,1,38.3,2,anionic,4.1,2.5
CS(=O)(=O)Nc1cc2c(c(oc2cc1)CCCC)C(=O)c1ccc(cc1)OCCCN(CCCC)CCCC,4.321928094887363,2.783557290571813,Dronedarone,141626-36-0,20.0,33.33,0.02,10.0,16.0,PDR. Accessed February 20 2013. http://www.pdr3d.com/detail.php?c=77881#section-14,MRT from VDss and Cl. 70 kg assumed. Ppb > 98%,,1992,556.76,7,1,89.1,18,zwitterionic,7.3,4.7
CSCCNc1nc(SCCC(F)(F)F)nc2n([C@@H]3O[C@@H]([C@H]([C@H]3O)O)CO[P@@](O[P@@](O)(=O)C(Cl)(P(O)(O)=O)Cl)(O)=O)cnc12,-4.836501267717121,-3.76778277797037,Cangrelor,163706-06-7,0.035,9.06,0.02,0.07,0.14," Akers Wendell S; Oh Jennifer J; Oestreich Julie H; Ferraris Suellen; Wethington Mary; Steinhubl Steven R. Pharmacokinetics and Pharmacodynamics of a Bolus and Infusion of Cangrelor: A Direct, Parenteral P2Y12 Receptor Antagonist. Journal of clinical pharmacology (2010), 50(1), 27-35.//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204958orig1s000clinpharmr.pdf. Accessed July 12 2017.","Digitized and then averaged from two groups. N=10 and N=9. 81 kg average with total dose 10 677 ug, and 79 kg average with total dose 20704 ug, respectively.",,1994,776.36,17,7,255.9,15,anionic,-1.4,-8.6
C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCNC(=N)N)NS(=O)(=O)c2cccc3CC(C)CNc23,-2.5563933485243853,-1.475325763147222,Argatroban,74863-84-6,0.17,5.0,0.46,0.57,0.4,"Hauptmann, J. Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs A review of small-molecule thrombin inhibitors. Eur J Clin Pharmacol  2002, 57,  751-758. ppb: The PDR states: Argatroban is 54% bound to human serum proteins, with binding to albumin and α1 – acid glycoprotein being 20% and 34%, respectively. Accessed January 7 2015. http://www.pdr3d.com/detail.php?c=135305#section-12.",,,1980,508.63,11,6,177.7,10,zwitterionic,1.5,-0.84
C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(=O)O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,3.906890595608519,2.2700043840775224,Artesunate,88495-63-0,15.0,1070.0,0.25,0.32,0.22,"Newton PN, Barnes KI, Smith PJ, Evans AC, Chierakul, W, Ruangveerayuth R, and WhiteNJ (2006) The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria.    Eur. J. Clin. Pharmacol.  62: 1003-1009.  Li Q, Xie LH, Haeberle A, Zhang J, and Weina P (2006) The evaluation of radiolabeled artesunate on tissue distribution in rats and protein binding in humans.  Am. J. Trop. Med. Hyg. 75: 817-826.",,,1982,384.42,8,1,100.5,5,neutral,3.0,2.9
Fc1ccc(cc1)[C@@H]2CCNC[C@H]2COc3ccc4OCOc4c3,4.169925001442312,3.10779907896424,Paroxetine,61869-08-7,18.0,18.0,0.06,17.0,13.0,"Lund J, Thayssen P, Mengel H, Pedersen OI, Kristensen CB, and Gram LF (1982) Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man.  Acta Pharmacol. Toxicol. 51: 351-357.  Paxil Product Label.",VDss was calculated from micro rate constants reported in the reference.,,1978,329.37,4,1,39.7,4,cationic,3.8,1.5
"N1(C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(=O)CCCC(C)C)C(C)C)=O)[C@H](O)C)=O)C(C)C)=O)C(C)C)=O)[C@@H](C(N[C@H](C(N[C@@H](C(N[C@@H]2C(N[C@@H](C(N[C@H](C(N[C@@H](Cc3ccccc3)C(N\C(C(N[C@H](C(O[C@@H]2C)=O)C(C)C)=O)=C/C)=O)=O)C(C)C)=O)[C@H](CC)C)=O)=O)[C@H](CC)C)=O)CCCN)=O)CCC1
",-3.1844245711374275,-1.9988404448178667,Kahalide F,149204-42-2,0.11,3.9,,0.48,0.57,"Jeany M. Rademaker-Lakhai, Simon Horenblas,Willem Meinhardt, Ellen Stokvis,Theo M. de Reijke, Jose´ M. Jimeno,Luis Lopez-Lazaro, Jose´ A. Lopez Martin, Jos H. Beijnen, Jan H.M. Schellens.Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer. Clin Cancer Res. 2005, Vol. 11, 1854–1862.",Average weight taken as 70 kg. Weighted average of multiple doses. From 320 to 930 ug/m2/d. N=28 overall. MRT from VDss and clearance. Somewhat lower clearance and VDss at higher doses (> 560 ug/m2/d) but all averaged.,,1993,1477.87,30,14,442.1,33,cationic,5.8,3.4
N12[C@@]([C@H]3N(CCC3)C([C@@H]1Cc1ccccc1)=O)(O[C@](NC([C@@H]1C[C@@H]3c4c5c(c[nH]c5ccc4)C[C@H]3[N@@](C1)C)=O)(C)C2=O)O,-1.5994620704162712,-0.4576737385981323,Dihydroergotamine,511-12-6,0.33,15.07,0.07,0.36,0.55,"J. KANTO, H. ALLONEN, K. KOSKI, M. KOULU, R. LAMMINTAUSTA, R. MANTYLA, T. KLEIMOLA, and T. SIlRTOLA. Pharmacokinetics of dihydroergotamine in healthy volunteers and in neuroiogical patients after a single intravenous injection. ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20148s7s8lbl.pdf. Accessed May 10 2017.","N=5, 70 kg average weight reported, 1 mg dose. MRT from clearance and VDss. Data were also digitized and, although the digitization was difficult, the VDss is very close to reported with a clearance somewhat inferior but within 20%. The data reported were deemed more reliable than those in Little et al and Wyss et al.","Data from Wysss et all seems inconsistent with labeling of plot and results after digitization. P. A. Wyss, J. Rosenthaler, E. Niiesch, and W. H. Aellig. Pharmacokinetic investigation of oral and IV dihydroergotamine in healthy subjects. Eur. J. Clin. Pharmacol. 1991 41, 597-602. Intially digitized and then discarded. Similarly, data digitized from Little et al. seemed to agree with Kanto et al but differed (~25% in clearance) even when the AUC was corrected to being only 10% different fom the data reported by Little and co-authors. Br. J. Clin. Pharmacol. 1982, 13 785-790.",1942,583.68,10,3,118.2,4,cationic,3.8,3.3
NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(=N)N)cc1,5.727920454563199,3.893275205599145,Pentamidine,100-33-4,53.0,74.0,0.09,12.0,25.0,"Conte JE, Duncan S, McKenna E, and Zurlinden E (1999) Effect of gender and race on the pharmacokinetics of pentamidine in HIV-infected patients.  Clin, Drug Invest. 17: 293-299.   fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191. ppb: Sihyung Yang,Tanja Wenzler,Patrik N. Miller, Huali Wu,David W. Boykin, Reto Brun Michael Zhuo Wang Pharmacokinetic Comparison To Determine the Mechanisms Underlying the Differential Efficacies of Cationic Diamidines against First- and Second-Stage Human African Trypanosomiasis. Antimicrobial Agents and Chemotherapy 2014, 58, 4064-4074",,,1939,340.42,6,4,118.2,10,cationic,2.5,-1.2
NC(=O)c1ncn(n1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O,3.807354922057604,2.2842652524791136,Ribavirin,36791-04-5,14.0,5.2,1.0,45.0,45.0,"Paroni R, DelPuppo M, Borghi C, Sirtoni CR, and Galli Kienle M (1989) Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers.  Int. J. Clin. Pharmacol. Ther. Toxicol. 27: 302-307.  Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, and McNamara P (1999) Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.  Antimic. Agents Chemother. 43: 2451-2456.  Morse GD, Shelton MJ, and O'Donnell AM (1993) Comparative pharmacokinetics of antiviral nucleoside analogues.  Clin. Pharmacokinet. 24: 101-123.",,,1962,244.2,9,4,143.7,3,neutral,-2.8,-2.8
NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N2CCC(CC2)N3Cc4ccccc4NC3=O)C(=O)N5CCN(CC5)c6ccncc6,-1.6896598793878497,-0.5180961333755326,Olcegepant,204697-65-4,0.31,2.6,,1.9,2.5,"Iovino M, Feifel U, Yong CL, Wolters JM, and Wallenstein G (2004) Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers.    Cephalalgia 24: 645-56.",,,1998,869.65,14,5,176.5,12,cationic,4.1,2.2
NCCCNc1ccc2c(CNCCO)nn3c4c(O)ccc(O)c4C(=O)c1c23,3.584962500721156,2.476439662008608,KW-2170,207862-44-0,12.0,18.0,,11.0,32.0,"Saeki T, Eguchi K, Takashima S, Sugiura T, Hida T, Horikoshi N, Aiba K, Kuwabara T, and Ogawa M (2004) Phase I and pharmacokinetic study of KW-2170, a novel pyrazoloacridone compound, in patients with malignant tumors.  Cancer Chemother. Pharmacol.  54: 459-468.",,,1998,397.43,9,6,145.7,8,cationic,-0.21,-3.6
N[C@@H]1[C@@H]([C@@H](O[C@H](O[C@@H]2c3c(O)c4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C[C@@](C2)(O)C(CO)=O)C1)C)O[C@@H]1CCCCO1,5.4329594072761065,3.905634687382398,Pirarubicin,72496-41-4,43.2,57.7,,12.5,11.1,"Dominique Marchiset-Leca,  Francois-Ren, Leca Anne Galeani, Alex Noble, Jacques Catalin Pharmacokinetics and metabolism of pirarubicin in humans: correlation with pharmacodynamics Cancer Chemother Pharmacol (1995) 36:239 243, 1995","Essentially a prodrug of doxorubicin. 80 courses of therapy over 27 patients. 1.73 m2/70 kg used as conversion factor. 25 to 50 mg/m2 in an average of 10 min infusion (5-15 min). Also, Nagasawa et al, J. Pharmacobio-Dynam., 1991, 14, 422-430. Data in 10 pediatric patients in agreement with cited paper.",Based on ratio of metabolites and parent in plasma. No excretion data available.,1978,627.64,13,5,204.3,7,zwitterionic,1.7,1.3
Nc1nc(N)c2nc(c(N)nc2n1)c3ccccc3,3.700439718141092,2.4291776069500908,Triamterene,396-01-0,13.0,63.0,0.42,3.4,4.3,"Gilfrich HJ, Kremer G, Mohrke W, Mutschler E, and Volger KD (1983) Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability.  Eur. J. Clin. Pharmacol. 25: 237-241.  Hasegawa J, Lin ET, Williams RL, Sorgel F, and Benet LZ  (1982) Pharmacokinetics of triamterene and its metabolite in man.  J. Pharmacokinet. Biopharm. 10: 507-523.",,,1954,253.26,7,3,129.6,1,neutral,1.1,1.1
O(C(=O)C(c1sccc1)(O)c1cccs1)C1C[C@@H]2[C@H]3O[C@H]3[C@H](C1)[N+]2(C)C,5.0,3.034890494267332,Tiotropium,186691-13-4,32.0,12.6,0.28,42.3,,"Tiotropium Bromide Monohydrate - FDA Approval Package
Label 021395/S-014. See also, Tiotropium Bromide Monohydrate - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 021395/S-000 Part 01. Accessed through Pharmapendium.",Structure and smiles refer to cation. 70 kg average weight assumed. MRT from VDss and clearance. T1/2 estimated between 5-6 days (~ 132 hours),"Tiotropium Bromide Monohydrate - FDA Approval Package
Label 021395/S-014. Accessed through Pharmapendium. 74% excreted unchanged.",1997,392.51,5,1,59.1,5,neutral,-2.3,-2.3
O(C)c1c2c3c(c(c1OC)Br)CCN([C@H]3Cc1cc(c(cc1)OC)Oc1ccc(C[C@H]3c4cc(O2)c(OC)cc4CCN3C)cc1)C,5.672425341971495,3.8844850803293656,Bromotetrandrine,62067-29-2,51.0,9.6,0.22,88.2,59.4," Zheng L; Qing Y-P; Xu N; Yu Q; Wang Y; Wang F-P; Li Z-Y. Pharmacokinetics and safety of bromotetrandrine (BrTet, W198) after single-​dose intravenous administration in healthy Chinese volunteers. Journal of clinical pharmacy and therapeutics (2010), 35(1), 113-119.//ppb: Xiao SH, Wei GL, Lu R, Liu CX, Wang FP. Pharmacokinetics of bromotetrandrin (W198) in rats and beagle dogs. Yao Xue Xue Bao. 2004, 39, 301-304. ","Data digitized from plot reported. N=10, 30 mg/m2 dose only. AUC reported 1311.3 ug.h/L. Calculated AUC 1279.4 ng.h/mL. From ppb reference (abstract): The plasma protein binding ratio of W198 with human serum protein was 78.0%.",,1977,701.65,8,0,61.9,4,cationic,8.3,7.2
O([C@@H]1[C@@H]([C@H]([C@H](O[C@@H]2[C@H](O[C@@H](OC[C@@H]([C@@H](\C=C\CCCCCCCCCCCCC)O)NC(CCCCCCCCCCCCCCCCC)=O)[C@@H]([C@H]2O)O)CO)O[C@@H]1CO)O)OC[C@@H]([C@@H]([C@H]1[C@@H]([C@H](C[C@](O1)(C(O)=O)O)O)NC(C)=O)O)O)[C@H]1[C@@H]([C@H]([C@@H](O)[C@H](O1)CO)O[C@@H]1O[C@@H]([C@H](O)[C@@H]([C@H]1O)O)CO)NC(C)=O,-3.8365012677171206,-2.829558651373569,Ganglioside GM1,37758-47-7,0.07,0.02,,55.0,77.4,"Rost, K. Ludwig; Brockmoeller, Juergen; Weber, Willi; Roots, Ivar. Multiple-dose pharmacokinetics of ganglioside GM1 after intravenous and intramuscular administration to
healthy volunteers. Clin. Pharmacol. Ther. 1991, 50, 141-149.","Ganglioside A2. Ganglioside G4. Ganglioside GM1A. N=3 subjects, 21 d dosing at 100 mg/day iv. 68.8 kg average weight. No data reported but indication that the compound is very highly bound to plasma proteins.",,1969,1546.82,34,20,540.6,52,anionic,-0.53,-4.0
O=C(Cc1csc(N)n1)Nc3ccc(CCNC[C@H](O)c2ccccc2)cc3,4.572889668420581,3.2225517051043884,Mirabegron,223673-61-8,23.8,13.6,0.29,29.3,50.0,"Mirabegron, prescribing information. PDR. Accessed July 31 2014. http://www.pdr3d.com/detail.php?c=91002#section-12","Assumed 70 kg as average weight.MRT from VDss and clearance.  See also:  Eltink, Charlotte et al. Int. J.  Clin. Pharmacol. Ther., 2012, 50, 838-849.",,1999,396.51,6,4,100.3,9,cationic,1.8,0.34
O=C1N(CCCCNC[C@H]2CCc3ccccc3O2)S(=O)(=O)c4ccccc14,-2.251538766995965,-0.8423578323009128,Repinotan,144980-29-0,0.21,2.2,,1.6,1.2,"Heining R,  Sundaresan P, Shah A and Boettcher M (2005) Effect of Gender and Age on the Pharmacokinetics of Repinotan.  Clin. Drug. Invest. 25: 125-134.  ",,,1992,400.49,6,1,75.7,7,cationic,3.9,3.5
OC(CCN1CCCC1)(C2CCCCC2)c3ccccc3,-0.4344028241457749,0.763688776278409,Procyclidine,77-37-2,0.74,0.86,,14.0,12.0,"Whiteman PD, Fowle ASE, Hamilton MJ, Peck AW, Bye A, dean K, and Webster A (1985) Pharmacokinetics and pharmacodynamics of procyclidine in man.  Eur. J. Clin. Pharmacol. 28: 73-78.",VDss calculated from digitized C vs t plot.,,1951,287.44,2,1,23.5,5,cationic,4.2,2.2
OC(Cc1cccnc1)(P(=O)(O)O)P(=O)(O)O,2.655351828612554,1.4392156032304635,Risedronic acid (Risedronate),105462-24-6,6.3,1.5,0.76,70.0,200.0,"Mitchell DY, Barr WH, Eusebio RA, Stevens KAP, Duke FP, Russell DA, Nesbitt JD, Powell JH, and Thompson GA (2001) Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration.  Pharm. Res. 18: 166-170.  See als:  Actonel Product Label. PDR. Accessed July 29 2014. http://www.pdr3d.com/detail.php?c=26372#section-13",,,1986,283.11,8,5,148.2,4,anionic,-2.2,-7.0
OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12,3.584962500721156,2.21400345088462,Mitoxantrone,65271-80-9,12.0,7.9,0.25,25.0,53.0,"Canal P, Attal M, Chatelut E, Guichard S, Huguet F, Muller C, Schlaifer D, Laurent G, Houin G, and Bugat R (1993) Plasma and cellular pharmacokinetics of mitoxantrone in high dose chemotherapeutic regimen for refractory lymphomas.  Canc. Res. 53: 4850-4854.  Scott LJ and Figgitt DP (2004) Mitoxantrone: a review of its use in multiple sclerosis.  CNS Drugs 18: 379-396.",,,1952,444.48,10,8,163.2,12,cationic,-0.37,-3.2
OC[C@@H](O)[C@@H](O)[C@H](O[C@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)N[C@@H](C)C(=O)NCCOP(O)(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(N)=O)[C@H](C=O)NC(C)=O,2.5360529002402097,1.092146835626897,Mifamurtide,83461-56-7,5.8,48.7,,1.98,2.05,"Karthik Venkatakrishnan,William G. Kramer, Timothy W. Synold, Daniel B. Goodman ,Evin Sides III, Cristina Oliva. A pharmacokinetic, pharmacodynamic,
and electrocardiographic study of liposomal mifamurtide
(L-MTP-PE) in healthy adult volunteers.  J Clin Pharmacol (2012) 68:1347–1355.",MTP-PE. Open form (sugar) reported by Scifinder and ChemIDPlus. Data reported in L and L/m2 (or corresponding units for clearance). 70 kg assumed. 4 mg dose in 30 minutes infusion. N=21. Liposomal preparation. MEPACT (approved in Europe),,1982,1237.5,25,10,383.9,58,anionic,4.9,1.4
O[C@@H]1[C@@H](C[C@](O)(C[C@H]1OC(=O)\C=C\c2ccc(O)c(O)c2)C(=O)O)OC(=O)\C=C\c3ccc(O)c(O)c3,2.269033146455237,1.0298547882991231,"3,5-DCQA",2450-53-5,4.82,75.81,,1.05,3.17,"Wen-Zheng Ju,Yang Zhao,Fang Liu,Ting Wua,Jun Zhang,Shi-Jia Liu,Lin gZhou,Guo-Liang Dai,Ning-Ning Xiong,Zhu-Yuan Fang. Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: Results of a randomized phase I study in healthy Chinese volunteers. Phytomed. 2015, 22, 319–325","3,5-dicaffeoylquinic acid. Data digitized from plot reported.  All from average males/females. 6 vials EH product tested for content via HPLC. 16.44 mg total dose, N=6, 57 kg average weight. 1 hr infusion. All AUCinf data within 10% of reported.",,1963,516.45,12,7,211.3,9,anionic,2.6,-1.1
Oc1ccc2c(Oc3cc(O)ccc3C24OC(=O)c5ccccc45)c1,-2.8365012677171206,-1.6244510017690346,Fluorescein,2321-07-5,0.14,1.3,0.11,1.8,1.6,"Larsen M, Loft S, Hommel E, and Lund-Andersen H (1988) Fluorescein and fluorescein glucuronide in plasma after intravenous injection of fluorescein.  Acta Opthamol. 66: 427-432.  ",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1931,332.31,5,2,76.0,0,neutral,3.9,3.9
[H]C#CCCCC(c1cc(c(c(c1)C(C)(C)C)O[H])C(C)(C)C)=O,3.584962500721156,2.300621304336589,Tebufelone,112018-00-5,12.0,8.9,,22.3,50.7,"Cruze CA, Kelm GR, Meredith MP (1995) Interspecies scaling of tebufelone pharmacokinetic data and application to preclinical toxicology. Pharm. Res. 12, 895-901.","Data digitized from Dedrick-like plot reported. AUC reported 579 ng.h.mL-1; clearance reported 9.87 mL.min-1.kg-1.  These data refer to the corrected t and C data for human. 25 mg dose and 72.9 average weight.
",,1987,300.44,2,1,37.3,6,neutral,5.4,5.4
[H]OC(CCCOCC=C1C[C@H]2C[C@H]([C@@H](C#C[C@H]([C@@H](C)CC#CCC)O[H])[C@H]2C1)O[H])=O,1.263034405833794,0.2445046664060958,Eptaloprost,90693-76-8,2.4,66.2,,0.59,0.41,"Hildebrand M, Inter-species Extrapolation of Pharmacokinetic Data of Three Procyclin-Mimetics, Prostaglandins, 1994, 48, 297-312."," t1/2=0.693/kel. 
Data reported and used for allometric scaling were taken from other publications by the same author.",,1984,402.52,5,3,87.0,15,anionic,3.0,0.22
[H]OC[C@@H](C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C(C)C)c1ccccc1,2.350497247084133,1.3222571358423678,Ipratropium,60205-81-4,5.1,31.4,0.95,2.7,1.64,"Ensing K., de Zeeuw R.A., Nossent  G.D., Koeter G.H, Cornelissen, P.J.G. et al. ( 1989)  Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. Eur. J. Clin. Pharmacol. 36, 189-194.   fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191","N=10, 74 kg average weight VDss calculated as sum of Vc, Valpha and Vbeta reported. 2 mg/dose administered in 20'. ",,1962,332.46,4,1,46.5,7,neutral,-0.72,-0.72
c1(N(CC)CC)cc2oc(C(Nc3ccc4c(c3)cc([nH]4)C(N3C[C@H](c4c5c([nH]cc5C)c(OC(=O)Nc5ccccc5)cc34)CCl)=O)=O)cc2cc1,-3.473931188332412,-2.373974174780133,Carzelesin,119813-10-4,0.09,2.9,,0.51,0.48,"Data as average of two different single patient profiles (N=2):   (1) Van Tellingen, Olaf; Nooijen, Willem J.; Schaaf, Larry J.; Van Der Valk, Martin; Van Asperen, Judith; Henrar, Roland E. C.; Beijnen, Jos H. Comparative pharmacology of the novel cyclopropylpyrroloindole-​prodrug carzelesin in mice, rats, and humans. Cancer Research (1998), 58(11), 2410-2416.     (2) van Tellingen O, Punt CJ, Awada A, Wagener DJ, Piccart MJ, Groot Y, Schaaf LJ, Henrar RE, Nooijen WJ, Beijnen JH. A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study. Cancer Chemother Pharmacol. 1998;41(5):377–384."," (1) data digitized from Fig. 4.  Dose 300 ug/m2 (0.0075 mg/kg), infusion T=10 min, N=1*. (2) data digitized from Fig. 5 (dose 210 ug/m2 (0.00525 mg/kg), infusion T=10 min, N=1**.
* reported data: see Table 4 (data seems to be for 3 patients (N=3) presented in Table 1 in van Tellingen O. et al, Cancer Chemother Pharmacol, 1998, 41, 377-384). The actual digitized values (AUC, CL, ...) seem to agree with the values reported for the last patient in Table 1.
** 48th patient in Table 1, reported data: see Table 1 where the AUC, CL, half times, ... for all patients are reported (CL = 0.29 L/h/kg)",,1988,729.22,11,4,136.0,10,neutral,7.7,7.7
c1(\C(CCCCOC)=N\OCCN)ccc(C(F)(F)F)cc1,4.554588851677638,3.5501999019169075,Fluvoxamine,54739-18-3,23.5,31.95,0.2,12.26,12.5,"J. van Harten, F. Kok, A. Lönnebo  and A. Grahnén. Pharmacokinetics of fluvoxamine after intravenous and oral administration. Eur. Neuropsychopharmacology, 1994, 4, 331.","Average of two doses, N=17 per dose, 70 kg/average weight assumed. 10 and 30 mg doses as iv infusion in 60 minutes. Clearance from dose/AUC, then averaged. MRT from VDss and clearance. ","Ppb from PDR label. Absolute BA from paper 53% (po dose 50 mg, crossover with iv doses)",1977,318.33,4,1,56.8,9,cationic,3.1,1.2
c1(\C=C\C(NCCO)=O)ccccc1,-3.1844245711374275,-1.9791122737183116,Idrocilamide,6961-46-2,0.11,0.99,,1.93,1.35,"H. Maier-Lenz, L. Ringelski, A. Windhorfer zur.Pharmakokinetik nnd Bioverfiigba1·keit des Myotonolytikums N-(Hydroxy-2-athyl)-cinnarnid. Arzneim.-Forsch. 1980, 30, 1813-1816.","LCB-29. Brolitene. N=10, 60 mg iv dose, 68 kg average weight
Reported AUC = 11.31 +/- 4.9 ug.hr/mL AUC computed as  14.8 ug.h/mL from plot digitization but within sd and thus accepted.
lambda z = 0.7 hr-1
VD reported = 7.4 L",,1948,191.23,3,2,49.3,4,neutral,0.86,0.86
c1(ccc(cc1)CCCCCCCC)CCC(CO)(N)CO,4.112700132749362,3.0717052878468003,Fingolimod,162359-55-9,17.3,1.53,0.002,189.0,144.0,"PP. Fingolimod Hydrochloride - FDA Approval Package
Pharmacology Review 022527/S-000 Part 04","MRT from VDss and Cl. N=11, (5M/6F) 1 mg dose iv injection, reported average weight 69.1 kg. Reported source, study A0108. ppb reported as 99.7 to 99.9% across species. 99.8% taken","PDR. Accessed February 21 2013. http://www.pdr3d.com/detail.php?c=64159#section-13.  After oral administration, about 81% of the dose is slowly excreted in the urine as inactive metabolites. Fingolimod and fingolimod-phosphate are not excreted intact in urine but are the major components in the feces with amounts of each representing less than 2.5% of the dose. ",1994,307.47,3,3,66.5,12,cationic,3.7,2.6
c1(cccc2c1C(c1c(O)c3c(c(c1C2=O)O)C[C@](C(CO)=O)(O)C[C@@H]3O[C@H]1C[C@@H]([C@@H]([C@@H](O1)C)O)[N@]1CCO[C@@H](C1)OC)=O)OC,5.614709844115208,4.518262989914922,Nemorubicin,108852-90-0,49.0,15.32,,53.3,49.2,"M Bakker, JP Droz, AR Hanauske, J Verweij, AT van Oosterom, HJM Groen, MA Pacciarini, L Domenigoni, F van Weissenbruch, E Pianezzola, EGE de Vries. Broad phase 11 and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. British Journal of Cancer 1998 77, 139-146.","FCE23762.  PNU-152243A, MMRDX. 1.5 mg/m2, N=11, 1.73 m2/70 kg factor used. Data from Table 5.",,1986,643.64,14,5,201.7,7,neutral,0.75,0.59
c12C(=NCC(=O)Nc1ccc(c2)Br)c1c(cccc1)Cl,-3.4900508536956893,-2.2421832967474,Phenazepam,51753-57-2,0.089,0.05,,28.31,14.88,"Maksutova E L; Sariev A K; Zherdev V P; Voronina T A; Zheleznova E V. The pharmacokinetic characteristics of fenazepam in epileptics. Eksperimental'naia i klinicheskaia farmakologiia. 1994, 57, 16-18.","VDss from clearance and MRT. N=5, 70 kg average weight assumed, 2 mg dose.",In house translation from Russian.,1974,349.61,3,1,41.5,1,neutral,3.8,3.8
c12[C@@H](c3ccc(O)cc3)CNCCc1c(c(O)c(c2)O)Cl,-1.0,0.1200615020068759,Fenoldopam,67227-56-9,0.5,41.5,0.12,0.2,1.0,"PP. Fenoldopam Mesylate - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 019922 1997-Sep-25  PDF(1763k)",N=12 healthy volunteers. 1 ug/kg/min dose. MRT from VDss and clearance.,"PP. Fenoldopam Mesylate - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 019922 1997-Sep-25  PDF(1763k)",1980,305.76,4,4,72.7,1,cationic,2.7,1.9
c12c(C(=N)N)cccc1\C(=N\NC(=N)N)CC2,4.321928094887363,2.685913516551102,Sardomozide,149400-88-4,20.0,3.2,,104.1,65.4,"A Phase I and Pharmacokinetic Study of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, Administered on a Dailytimes-five every-three-week Schedule in Patients with Advanced Solid Malignancies. Lillian L. Siu, Eric K. Rowinsky, Lisa A. Hammond, Geoffrey R. Weiss,Manuel Hidalgo, Gary M. Clark, Judy Moczygemba, Les Choi, Ron Linnartz, Nicholas C. Barbet, Ivo T. Sklenar, Renaud Capdeville, Gregory Gan, Carl W. Porter, Daniel D. Von Hoff, and S. Gail Eckhardt. Clin. Cancer Res. 2002, 8, 2157–2166. ",SAM486A or CGP48664.  Weighted average across several doses (3.6 to 202.8 mg/m2/day) and 18 patients. Total VDss calculated 811 L/m2 for 18 patients. Clearance 7.75 L/h/m2. 1.73m2/70 factor used.  T1/2 on 19 patients. MRT = VDss/Cl. Highly variable PK. ,,1993,230.27,6,5,124.1,3,cationic,-0.14,-5.0
c12c(N(C(c3cc4cc(NC(Nc5cc6c([nH]c(c6)C(N6c7c(c8c([nH]cc8C)c(c7)O)[C@@H](C6)CCl)=O)cc5)=O)ccc4[nH]3)=O)C[C@H]2CCl)cc(O)c2c1c(c[nH]2)C,-4.321928094887363,-2.973087875715044,Bizelesin,129655-21-6,0.05,0.5,,1.7,1.6,"Pitot, Henry C.; Reid, Joel M.; Sloan, Jeff A.; Ames, Matthew M.; Adjei, Alex A.; Rubin, Joseph; Bagniewski, Pamela G.; Atherton, Pamela; Rayson, Daniel; Goldberg, Richard M; Erlichman, Charles. A phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. Clin. Cancer Res. 2002, 8, 712-717.",Weighted average over 17 patients with doses ranging from 0.1 ug/m2 to 1 ug/m2.  1.73m2/70 kg conversion factor used.,,1990,815.7,13,8,185.4,6,neutral,5.9,5.9
c12c(cccc1cncc2)OCC(N[C@H](C(N[C@H]([C@@H](C(N1[C@@H](CSC1)C(NC(C)(C)C)=O)=O)O)Cc1ccccc1)=O)CSC)=O,-3.1844245711374275,-2.027631719334356,KNI-272,147318-81-8,0.11,10.5,,0.17,0.44,"BRIGITTA U. MUELLER, BARRY D. ANDERSON, MAUREEN Q. FARLEY, ROBERT MURPHY, JUDY ZUCKERMAN, PAUL JAROSINSKI, KAREN GODWIN, CINDY L. MCCULLY, HIROAKI MITSUYA, PHILIP A. PIZZO, FRANK M. BALIS. Pharmacokinetics of the Protease Inhibitor KNI-272 in Plasma and Cerebrospinal Fluid in Nonhuman Primates after Intravenous Dosing and in Human Immunodeficiency Virus-Infected Children after Intravenous and Oral Dosing. Antimicr. Agents Chemother. 1998, 42, 1815-1818.","Kynostatin 272. Dosed to children at 200 mg/m2 to children. Median age 9.7 years, N=5 from data in table 2. MRT from VDss and clearance.",,1992,667.84,11,4,150.0,13,neutral,2.0,1.9
c12c3c([C@@]4(O[C@@H](O3)[C@@H](O)[C@@H]([C@@H]4O)N(C)C)C)cc(c1C(c1c(c3[C@@H](C[C@@](Cc3cc1C2=O)(C)O)OC)O)=O)O,3.192194165283345,1.9196283287795497,Menogaril,71628-96-1,9.14,11.61,,13.13,13.22,"Merrill J. Egorin, David A. Van Echo, Margaret Y. Whitacre, Alan Forrest, Lawrence M. Sigman, Kathrin L. Engisch, and Joseph Aisner (1986). Human Pharmacokinetics, Excretion, and Metabolism of the Anthracycline Antibiotic Menogaril (7-OMEN, NSC 269148) and Their Correlation with Clinical Toxicities. CANCER RESEARCH 46, 1513-1520",NSC 269148. Menogarol. 7-OMEN. Average clearance and VDss as reported by authors. 1.73 m2/70 factor used. Overall 24 stuides at different doses (infusion). MRT from clearance and VDss.,"From paper cited: In humans, as in rabbits (8), neither urinary or biliary excretion of 7-OMEN and its fluorescent metabolites represented a major route of drug clearance.",1978,541.55,11,5,166.2,2,zwitterionic,1.4,-1.2
c12c3cccc1cc(cc2C(=O)N(C3=O)CCN(C)C)[N+](=O)[O-],3.4982508675278257,2.483444644430901,Mitonafide,54824-17-8,11.3,34.6,,5.6,28.7,"Pharmacokinetics characterization of mitonafide in man. Brode E, Poveda Velasco A, Díaz-Rubio E, Rosell Costa R, Benavides Fissure A. Meth. Find. Exp. Clin. Pharmacol. 1992, 14(2), 131-140",Individual subject plasma levels and PK data reported. Data corrected for individual surface area and weight and then averaged. Very long t1/2 (gamma),,1975,313.31,7,0,83.8,4,neutral,2.3,2.1
c1c(c2c(cc1)C(=O)c1c(c(O)c3c(c1O)[C@@H](O)[C@@](O)(CC)C[C@@H]3O[C@@H]1C[C@@H]([C@@H]([C@@H](O1)C)O)N1CCOCC1)C2=O)O,4.38543103719352,2.91362074986835,KRN8602,105026-50-4,20.9,42.8,0.09,8.0,10.7,"Kerrie Clarke, Russell L. Basser, Darryl Maher, Denis J. Morgan, Jonathan Cebon, Richard M. Fox, John S. Hill, Carole Alt, Jane Bartlett, Howard Geldard, Andrew H. Kaye, and Michael D. Green. Phase I and Pharmacokinetic Study of KRN8602 Alone and With Filgrastim in Patients With Advanced Cancer. J Clin Oncol. 1998, 16:2181-2187.",Weighted average of 27 patients receiving KRN 8062 only. 10-50 mg/m2 dose range. 70-kg weight assumed. AUC units not reported. CAS of HCl salt.,,1986,585.6,12,6,186.4,4,neutral,1.4,1.2
c1c(cc2[nH]c(n3C[C@@H]([N@@](Cc1c23)C\C=C(\C)C)C)=S)Cl,4.458119481174506,3.448509650959088,R 82913,126347-69-1,21.98,10.41,,35.17,25.96,"De Wit S; Hermans P; Sommereijns B; O'Doherty E; Westenborghs R; van de Velde V; Cauwenbergh G F; Clumeck N. Pharmacokinetics of R 82913 in AIDS patients: a phase I dose-​finding study of oral administration compared with intravenous infusion. Antimicr. Agents Chemother. 1992, 36, 2661-2663.","9-Cl-TIBO. TIBO-R 82913. N=5, Day 29 infusion, 1 hr, 100 mg dose. Data digitized from plot. 70 kg average weight assumed. Only AUC0-24 after Day 29 and Day 0 was reported and the AUC 24 after digitization was about ~86% and thus considered acceptable. However, all data were calculated using the calculated AUCinf (2286 ng.hr.mL-1) obtainded from digitization. SOme accumulation observed (Day 0 to Day 29) but limited to 40%.  ",,1990,321.87,3,1,24.0,2,neutral,5.0,1.7
c1c(sc(N(Cc2cc3c(cc2)[nH]c(nc3=O)C)C)c1)C(=O)N[C@@H](CCC(O)=O)C(=O)O,2.715893370547605,0.7132446371783558,Raltitrexed,112887-68-0,6.57,0.9,0.05,123.0,140.0,"I Judson, T Maughan, P Beale, J Primrose, P Hoskin, J Hanwell, C Berry, M Walker and F Sutcliffe. Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694) British Journal of Cancer (1 998) 78(9). 1188-1193. ppb: Stephen J. Clarke, Philip J. Beale and Laurent P. Rivory. Clinical and Preclinical Pharmacokinetics of Raltitrexed. Clin Pharmacokinet 2000 , 39 (5): 429-443. From the ref. the authors cite own original work and state: Using ultrafiltration, binding was shown to be approximately 95% over a range of plasma concentrations. Therefore the review article data was accepted. ","Tomudex, ZD1694. Dose 3.0 mg/m^2 i.v. 15-min infusion (N=8, with normal renal function) Avg weight = 75 kg. Extremely long gamma phase. 3 compartment study.",,1987,458.49,10,4,152.7,9,anionic,1.6,-3.4
c1cc(ccc1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCc2cnc3c(n2)c(=O)nc([nH]3)N,3.277984747299765,2.0591588153519784,Folic acid,59-30-3,9.7,52.0,0.5,3.1,2.6,"Menke A; Weimann H J; Achtert G; Schuster O; Menke G. Absolute bioavailability of folic acid after oral administration of a folic acid tablet formulation in healthy volunteers. Arzneimittel-Forschung (1994), 44(9), 1063-1067// ppb: Elsborg L. Binding of Folic Acid to Human Plasma Proteins. Acta Haematol 1972,48, 207–212.","N=17. Dose = 5 mg  6min infusion. BW = 87.5 kg
PK iv profile reported in table 1. Concentration corrected from predose level of 18.2 ng/mL. MRT Calculated from VDss and CL.
AUC0-12h (ng*h/mL) = 1546 (reported 1550). AUC0-inf (ng*h/mL) = 1601",,1946,441.4,13,6,213.3,9,anionic,-1.3,-8.6
c1ccc(cc1)CC[C@H](N[C@@H]1C(N2[C@@H](CCC[N@@]2CCC1)C(O)=O)=O)C(O)=O,1.8875252707415875,0.5243194529621336,Cilazaprilat,90139-06-3,3.7,2.1,,29.5,50.6,"P. E. O. WILLIAMS, A. N. BROWN, S. RAJAGURU, R. J. FRANCIS, G. E. WALTERS, J. McEWEN & C. DURNIN. The pharmacokinetics and bioavailability of cilazapril in normal man. Br. J. Clin. Pharmacol. 1989, 27, 181S-188S","N=12, 74 kg average weight, 2.5 mg dose.
Reported AUC (0-24) = 192 ng.hr/mL
Clearance (24hr) = 12.3 L/h (= 2.8 mL/min/kg)
ppb variable from 24% at high concentration and 95% at low concentration (not reported)",91% excreted unchanged as per Williams et al.,1984,389.45,8,3,110.2,7,anionic,0.35,-5.4
